Prelude Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Prelude Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-35.6%
Buyback Yield
| Total Shareholder Yield | -35.6% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PRLD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRLD's dividend payments have been increasing.
Dividend Yield vs Market
| Prelude Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PRLD) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (PRLD) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PRLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PRLD's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PRLD has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prelude Therapeutics Incorporated is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Graig Suvannavejh | Goldman Sachs |